Document Type
Conference Proceeding
Abstract
- Eptacog alpha is the factor VII product on formulary
- It is approved by the FDA to treat bleeding in adults or children with hemophilia A or B with inhibitors •
- Additional approved uses include Glanzmann’s Disease, and factor VII deficiency and off label uses include cardiac surgery, and trauma salvage therapy
- Eptacog beta is an alternative recombinant factor VII product approved by the Food and Drug Administration in 2020 to treat bleeding in patients 12 years old or greater with hemophilia A or B with inhibitors
- In evaluating contracting pricing for each of these factor agents eptacog beta is potentially cheaper
Publication Date
12-2021
Recommended Citation
Rivera, Kevin Jr., PharmD; Renzoni, Anthony PharmD, BCPS, BCEMP; and Zahn, Evan PharmD, BCCCP, BCEMP, "Evaluation of Cost Savings Opportunity with the Use of an Alternative Factor VII Product within a Tertiary Academic Medical Center and Health System" (2021). Posters. 23.
https://scholar.bridgeporthospital.org/poster_presentations/23
COinS
Comments
Presented at the 56th Annual ASHP Midyear Clinical Meeting; virtual meeting December 5-9, 2021. Disclosure: The authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Kevin Rivera Jr: Nothing to disclose, Anthony Renzoni: Nothing to disclose, Evan Zahn: Nothing to disclose.